» The Paris Saclay Cancer Cluster is the winner of the Biocluster program « France 2030 » MyPharma Editions

Posted on Tuesday, December 6, 2022

During the monitoring committee of the ten-year strategy to fight cancer, the Minister of Higher Education and Research, Sylvie Retailleau, announced yesterday that the Paris Saclay Cancer Cluster (PSCC), dedicated to oncology, is the first winner of the Biocluster Call to the Expression of Interest (AMI). Launched within the framework of the “France 2030” plan presented by the President of the Republic Emmanuel Macron, this AMI aims to create “global centers of excellence that bring together companies, care, research and cutting-edge innovation, [avec] ambition to transform the landscape of French biomedical research”.

Cancer kills 1.3 million people in the European Union each year and continues to rise sharply (+25% expected by 2035). France has recognized excellence in fundamental research and clinical patient management, but struggles to translate these strengths into therapeutic and diagnostic solutions developed in France for the benefit of patients.

It is on the basis of this observation that Gustave Roussy, Inserm, the Institut Polytechnique de Paris, Sanofi and the University of Paris-Saclay wanted to create the PSCC, the missing link in the transformation of excellence in French fundamental cancer research into industrial diagnostic solutions and therapeutics developed in France. A real catalyst, the PSCC aims to facilitate and accelerate industrial projects and the maturation of start-ups, boost the French economy and generate jobs throughout the country, in a hypercompetitive international context. A first circle of key partners quickly joined the PSCC: UNICANCER, Assistance Publique-Hôpitaux de Paris, Institut Curie and the Medicen competitiveness cluster, and more than 60 other partners, including the Servier Group and several dozen start-ups . expressed interest.

The 80 to 100 million euros that will be received from the State over 10 years under “France 2030” will be a decisive lever for the development of the PSCC. This state support will be complemented by other investments, both public and private, including an important contribution already announced by Sanofi. These funds will make it possible to structure an offer oriented towards innovative projects with a single point of entry and simplified access to a set of services and platforms: better expertise in oncology, health data and biological samples, specialized technological platforms, access to financing and follow-up in each development stage, to support for conducting phase I and II clinical trials.

The heart of the cluster will be located in Villejuif, close to Gustave Roussy, in a rapidly developing area (ZAC Campus Grand Parc) that will soon be accessible by metro from Paris (lines 14 and 15). Industrial projects, from start-ups to the R&D team of a large group, will be able to settle there to be closer to the ecosystem and benefit from the PSCC offer, in an environment that encourages the meeting and cross-fertilization of talents and expertise .

The PSCC will animate this ecosystem, facilitate cooperation and help with funding. The first calls for projects will take place in 2023 for the launch of support and the first platforms by the end of next year.

Unique in Europe for its size and ambition, the mission of the Paris Saclay Cancer Cluster is to accelerate the development of innovations in the territory and make them available to patients more quickly. Its international reach will position France among the world leaders in converting science into value in the field of oncology, for patients and society as a whole.

“We are honored to have been selected today by the State as part of the France 2030 Framework. The PSCC will bring industrialists – mature and future – closer to the multidisciplinary expertise of the academic ecosystem, in order to develop the treatments and diagnostic tests of tomorrow’s France that will enable concretely improve the lives of cancer patients. comments Prof. Eric Vivier, President of the Paris Saclay Cancer Cluster.

“We are able to support the development of innovative projects. The PSCC intends to accelerate its maturation by betting, namely, on access through a single point of entry to a set of services and expertise that allow start-ups to grow and pharmaceutical companies to develop their solutions in the territory. » declares Benjamin Garel, managing director of the Paris Saclay Cancer Cluster association.

Source: Gustave Roussy

Leave a Comment